EPIX ESSA Pharma Inc. gains 138% Jan 27, 2021

ESSA Pharma Inc., a clinical-stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is headquartered in Vancouver, Canada.http://www.priceseries.com/trade/EPIX-ESSA-Pharma-Inc-stock-gains-138-percent-a-Trade-Record-by-priceSeries-2020121020210127.html